您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > EC359
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
EC359
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
EC359图片
CAS NO:2012591-09-0
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
EC359 是一种有效的,选择性的,高亲和力的和口服的生物利用度白血病抑制因子受体 (LIFR) 抑制剂,其 Kd 值为 10.2 nM,可直接与 LIFR 相互作用以有效阻断 LIF/LIFR 相互作用。
Cas No.2012591-09-0
Canonical SMILESC[C@@]12[C@](O)(C(F)(F)C#C)CC[C@@]1([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(C6=C(C)C=C(C)C=C6C)C=C5)C2)=O
分子式C36H38F2O2
分子量540.68
溶解度DMSO: 125 mg/mL (231.19 mM)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

EC359 is a potent, selective, high affinity and orally active leukemia inhibitory factor receptor (LIFR) inhibitor with a Kd of 10.2 nM, which directly interacts with LIFR to effectively block LIF/LIFR interactions[1].

[1]. Viswanadhapalli S, et al. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 Aug;18(8):1341-1354.